Incentives to use generic medicines

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Incentives to use generic medicines

Genéricos/Investigación | Posted 01/10/2010 0 Post your comment

A variety of financial and non-financial incentives are intended to encourage generic prescribing. Physician budgets are used by Germany and UK and seem to encourage generic prescribing. Assistance in terms of electronic prescribing, medicines databases, audit and feedback on prescribing data, guidelines and formularies tend to be voluntary and have a limited impact. Denmark and the UK teach medical students to prescribe by INN rather than brand name. Portugal requires prescription by INN if a generic product exists. Physicians see this as a restriction on their prescribing freedom in Belgium and France and resist such moves.

Generic substitution by a pharmacist means that when a physician prescribes a specific medicine, the pharmacist either may, or must, replace it by a generic medicine. In 2004 generic substitution was legally permitted in 70% of countries surveyed. The exact rules vary. Where generic substitution is allowed, physicians can override a decision to substitute in 89% of countries by annotating the prescription. The pharmacist has a duty to inform the patient that a substitution has been made.

Generic substitution must be financially attractive to pharmacists if it is to be successfully implemented. Remuneration as a fixed percentage of the cost encourages delivery of originator drugs in Portugal and Spain. Choosing to dispense generics is financially neutral in Belgium and advantageous in France and The Netherlands.

Patient co-payment makes the patient aware of the cost of their medicines. It may take the form of payment of a percentage of the cost of medicine (36% of countries), payment if the selected medicine is above a reference price (34% of countries), a fixed amount per prescription or another form. However, the financial pressure dissipates if the patient has insurance above the minimum obligatory level (as is common in France). If the co-payment is a percentage of the cost of medicines, patients have a financial incentive to demand cheaper generic medicines. For instance, in Poland, physicians tend to prescribe generic medicines because they are conscious of the limited ability of patients to meet co-payments and because they have long-term, positive experience with generic medicines. Patient co-payments may reduce access and equity and there is a cost in operating the system.

Related articles

An industry view of generic manufacturing

Pricing strategies in generic medicines

Can we have our cake and eat it?

The current EU regulatory framework governing biosimilars

Technical challenges in defining mAbs

What clinical trials will be required for biosimilar mAbs?

How far does similarity go?

International comparison of generic medicine prices

European generic prescribing trends and biosimilars

References

Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol. 2008;1(4):497-503.

Gosden T, Torgerson DJ. The effect of fundholding on prescribing and referral costs: a review of the evidence. Health Policy. 1997;40(2):103-14.

Wilkin D, Coleman A, Dowling B et al. National Tracker Survey of Primary Care

Groups and Trusts 2001/2002: Taking Responsibility? National Primary Care Research and Development Centre. Manchester and King’s Fund, London, UK. 2002.

European Generic Medicines Association (EGA). A review on the European generic pharmaceutical market in 2005. EGA, Brussels, Belgium. 2005.

Antoñanzas F, Oliva J, Pinillos M, et al. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur J Health Econ. 2007;8(3):297-300.

Gouveia Pinto C, Teixeira I. Pricing and reimbursement of pharmaceuticals in Portugal. Eur J Health Econ. 2002:3(4):267-70.

Willert PL. Assessment of the pharmaceutical market in Poland after accession to the European Union. Eur J Health Econ. 2007;8(4):347-57.